-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Observations on patents and other IP from a dual-licensed practitioner
Interesting news item from last week: according to Allergan’s web site, on September 8 Allergan and the Saint Regis Mohawk Tribe announced that Allergan had assigned several patents to the…
In October I wrote about the paragraph IV challenge to Eli Lilly’s anti-lung cancer drug Alimta®, royalties from which had paid in full for a new $280 million chemistry building…
Yesterday the latest copy of my college alumni magazine arrived. The magazine included an article on the campus’ new chemistry building, built at a cost of about 280 million dollars,…
As noted here and elsewhere, The Medicines Company (TMC) failed to secure a patent term extension (PTE) for US 5,196,404, its patent on bivalirudin, a peptide drug that is…
(revised September 6, 2009) The Medicines Company (TMC) has a problem. US 5,196,404, the patent that covers its product bivalirudin (sold in the USA under the name Angiomax®), will…
I’m Dan Feigelson. I’ve been practicing patent law for over 30 years. I’m also opinionated, as you may discover in reading my writings here.
America-Israel Patent Law Blog 